Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma

Phase 2 Terminated 12 enrolled Dartmouth-Hitchcock Medical Center National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have leptomeningeal metastases from a solid tumor or lymphoma.

Timeline

Start: 2000-01
Primary completion: 2004-05
Completion: 2004-05

Outcome

Outcome not reported

Stopped: “No objective response documented, protocol terminated after 12 patients.”

Publications

Results Davis TH, Fadul CE, Glantz MJ, et al.: Pilot phase II trial of temozolomide for leptomeningeal metastases: preliminary report. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-460, 2003. ISBN 1932312021

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Temozolomide	Small molecule	75 mg/m2	Oral